Novartis’ Kisqali improves survival in MONALEESA-3 participants
Kisqali has been developed by the Novartis Institutes for BioMedical Research. Credit: Novartis AG.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
